Discover how the Inventus Connect eSIM solutions, designed specifically for provisioned devices in clinical trials, are ...

Foghorn Therapeutics has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug ...

Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

Medtronic reported that a patient has completed the first procedure with the latest version of its ingestible camera, used to ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...

BeiGene has struck a $150 million deal to license a cancer candidate from CSPC Zhongqi Pharmaceutical Technology, positioning ...

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia ...

Billion-dollar biotech startup Xaira is expanding its C-suite with some top pharma talent. After wrapping up a 16-year tenure ...

Boundless Bio’s freshman year on the public markets hasn’t been easy, with “modest” layoffs in the summer followed by news ...